Printer Friendly

Re: Biomarkers in Active Surveillance.

EDITORIAL COMMENT

Prostate cancer (PCa) is a common health problem and the majority of PCa's are accepted as an innocent cancer. Active surveillance (AS) is an approach for management of low-risk PCa. However, there remain challenges in patient selection and monitoring protocols for AS. Actual methods for AS are highly invasive, expensive or inadequate. For these reasons, there is substantial interest in identifying markers. In this review, the authors summarized the evidence on serum, urine and tissue markers in AS. Serum markers include prostate specific-antigen (PSA) kinetics during AS as PSA doubling time, PSA uelocity, PSA density or the percent free PSA. Two new PSA-based blood tests incorporating free PSA are the Prostate Health Index and 4K score. Several urinary markers, such as PCa antigen 3 and the TMPRSS2: ERG gene fusion or DNA methylation patterns of urinary sediment, have also been explored for use in PCa detection and management. In addition to these methods, multiple tissue-based markers are available including the Oncotype DX Genomic Prostate Score, Prolaris Cell Cycle Progression Score, GenomeDx Decipher Score, etc. and immunohistochemical staining for inactivation of the PTEN gene. Very few markers have long-term results available for patients during AS. In addition to the actual AS protocols as PSA, digital rectal examination, rebiopsy or mp-magnetic resonance imaging, there is not yet well described unique protocol for patients under AS. In the near future, we believe that more accurate protocols will be suggested for patients under AS.

Fehmi Narter, MD, PhD

Loeb S (1), Tosoian JJ (2)

(1) New York University Faculty of Medicine, Department of Urology; New York University Faculty of Medicine, Department of Population Health; The Manhattan VA, New York, USA

(2) Johns Hopkins School of Medicine, The James Buchanan Brady Urological Institute, Baltimore, Maryland, USA Transl Androl Urol 2018;7:155-159. doi: 10.21037/tau.2017.12.26.

Doi: 10.4274/jus.2018.05.028

COPYRIGHT 2018 Galenos Yayinevi Tic. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Basic Research
Author:S., Loeb; J.J., Tosoian
Publication:Journal of Urological Surgery
Article Type:Editorial
Date:Dec 1, 2018
Words:313
Previous Article:Re: Actiuated Omentum Slows Progression of CKD.
Next Article:Adenocarcinoma of the Urinary Bladder: Mesane Adenokarsinomu.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |